tiprankstipranks
Argent Biopharma (AU:RGT)
ASX:RGT

Argent Biopharma (RGT) Income Statement

2 Followers

Argent Biopharma Income Statement

Last quarter (Q4 2022), Argent Biopharma's total revenue was AU$―, a decrease of ― from the same quarter last year. In Q4, Argent Biopharma's net income was AU$―. See Argent Biopharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Jun 23Jun 22Jun 21Jun 20Jun 19
Total Revenue
-AU$ 3.39MAU$ 4.74MAU$ 2.96MAU$ 2.08MAU$ 656.24K
Cost of Revenue
-AU$ 1.94MAU$ 2.92MAU$ 1.65MAU$ 1.90MAU$ 356.64K
Gross Profit
-AU$ 1.45MAU$ 1.82MAU$ 1.31MAU$ 174.66KAU$ 299.60K
Operating Expense
-AU$ 17.21MAU$ 16.07MAU$ 13.38MAU$ 11.98MAU$ 9.34M
Operating Income
-AU$ -15.76MAU$ -14.25MAU$ -12.07MAU$ -11.80MAU$ -9.04M
Net Non Operating Interest Income Expense
-AU$ -257.16KAU$ -209.84KAU$ 361.50KAU$ -123.25KAU$ 193.85K
Other Income Expense
-AU$ -637.88KAU$ 1.24MAU$ -3.01MAU$ -6.84MAU$ 6.97M
Pretax Income
-AU$ -21.13MAU$ -20.77MAU$ -15.44MAU$ -18.77MAU$ -1.88M
Tax Provision
-AU$ 2.02K-AU$ -27.28KAU$ 0.00AU$ 27.32K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
-AU$ -20.82MAU$ -20.77MAU$ -15.87MAU$ -19.36MAU$ -2.31M
Basic EPS
----AU$ -0.01AU$ >-0.01
Diluted EPS
----AU$ -0.01AU$ >-0.01
Basic Average Shares
----AU$ 1.38BAU$ 1.21B
Diluted Average Shares
----AU$ 1.38BAU$ 1.21B
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
-AU$ 19.15MAU$ 18.99M---
Net Income From Continuing And Discontinued Operation
-AU$ -20.82MAU$ -20.77MAU$ -15.87MAU$ -19.36MAU$ -2.31M
Normalized Income
-AU$ -12.58MAU$ -20.77MAU$ -15.46MAU$ -13.64MAU$ -116.55K
Interest Expense
----AU$ 135.58KAU$ 8.00K
EBIT
-AU$ -20.87MAU$ -20.56MAU$ -15.80MAU$ -18.63MAU$ -1.87M
EBITDA
-AU$ -20.12M--AU$ -18.15MAU$ -1.61M
Currency in AUD

Argent Biopharma Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis